Traditional Tablets Will Lose Market Share Due to Increased Use of Modified Release Technologies

Informing the pharmaceutical drug development, manufacturing and commercialization industry.

CARY, NC – May 31, 2017 – The 2^nd edition of Industry Standard Research’s (ISR’s) Oral Dosage Forms Market Overview and Outlook report offers details on how industry utilization rates of seventeen different oral dosage forms will shift over the next five years as new technologies and capabilities impact this classic dosage form, including current and projected portfolio composition, outsourcing frequency and outsourcing expenditure.

“Traditional tablets – those without added functionality – will compose a smaller proportion of drug innovators’ oral dosage form product portfolios over the next five years, and will be particularly impacted by increased use of modified release technologies,” explained Kate Hammeke, Vice President, market research at ISR. “More than two-thirds of research participants mentioned that the company they work for is investigating improving products or extending the life cycle through added drug delivery functionality. The most popular way research participants mentioned that their companies are doing this is the application of modified release mechanisms. Life cycle extension strategies will have a direct impact on which oral dosage forms gain in use in the coming years.”

Key statistics from the report include the volume of oral solid dose manufacturing projects, the proportion of which are outsourced (overall and broken out by oral dosage form), which dosage forms will grow in usage over the next five years and which may lose market share. ISR’s analysis includes cuts of data to show differences by company size and outsourcing volume. Understanding these dynamics will help both drug innovators and contract manufacturers to better evaluate their position in the marketplace and prepare for upcoming changes and new trends in oral dosage forms.

In addition, ISR explores the perceptions and selection of oral dosage contract manufacturers for both complex and simple projects. The data reveal top selection drivers, the reasons CMOs lose bids and drug innovators’ use of preferred providers and/or offshore contract manufacturers when outsourcing oral dosage form manufacturing projects.

Familiarity, Consideration (for simple and complex projects), Use and Preference among oral dosage CMOs – including verbatim feedback from recent users – information is included for the following contract manufacturers: Acino, Aenova, Aesica, Alcami, Alkermes, Almac, Aptuit, Bend Research (Capsugel Dosage Form Solutions), Catalent, CMIC, Corden, Confab/DPT, CoreRx, Dr. Reddy’s CPS, Fareva, Famar, Formex, Glatt Pharmaceutical Services, Metrics, NextPharma, NIPRO, Norwich, Patheon, Pfizer CentreOne, PharmaTech Industries, Pii, Piramal Pharma Solutions, Recipharm, Rottendorf Pharma, Siegfried, Unither, UPM Pharmaceuticals, WellSpring Pharma, Wockhardt, Xcelience (now part of Capsugel).

For more information on ISR’s Oral Dosage Forms Market Overview and Outlook (2^nd Edition) report, please visit ISR’s report page.

About Industry Standard Research

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at www.ISRreports.com, email info@ISRreports.com, or follow ISR on Twitter @ISRreports.